Article
The recruitment imperative: Why sites and patients determine cardiometabolic trial success
Cardiometabolic drug development is advancing rapidly, with obesity, diabetes, renal, metabolic and cardiovascular (CV) disease converging into one outcomes story. As studies grow larger, more global and more complex, competition for sites and patients is intensifying.